📋 Tender Overview
Amyotrophic lateral sclerosis ALS is a progressive neurodegenerative disease that affects nerve cells in the brain and the spinal cord. As of now there is no known cure but researchers at The Jackson Laboratory JAX and elsewhere are undaunted and hard at work.Amyotrophic lateral sclerosis ALS is a progressive neurodegenerative disease that affects nerve cells in the brain and the spinal cord. As of now there is no known cure but researchers at The Jackson Laboratory JAX and elsewhere are undaunted and hard at work.One of the main issues with treating ALS is that its not just one disease. Much like Alzheimers Disease Parkinsons and other diseases were not sure how many specific types of ALS exist genetically says JAX Professor Rob Burgess Ph.D. Is it five different types of disease 10 500 They all may look similar but the differences only emerge when you try to treat the disease at the cause.Breaking ALS research down on a genetic levelThere is functionally no treatment for ALS right now and Burgess says that if a breakthrough were to come it would materialize if scientists could identify the genetic variations of ALS and treat it like a matrix of separate diseases.The Burgess Lab is helping to identify some of the basic molecular mechanisms in the peripheral neuromuscular junction and the retina. Uncovering more information about the genetics of neuromuscular and neurodevelopmental disorders could yield new treatments for any disease under that umbrella. Their work is finding the why and how of these neurological genetic disorders which is essential if researchers can ever unlock how to treat or prevent ALS.Burgess isnt the only JAX researcher working to solve the ALS puzzle. Associate Professor Greg Cox Ph.D. who works with Burgess on some of the gene isolation work runs a lab trying to hunt down the molecular pathways underlying degenerative motor neuron diseases in humans such as spinal muscular atrophy SMA and ALS.The genetics of neurodegenerative diseasesCox mainly looks at genetic mouse models that develop similar symptoms to ALS and works to identify the genes that may be causing these issues. Isolating the genetic cause of neurodegenerative disease in mouse models can be a painstaking task and Cox is in a uniquely beneficial place to do it.The great thing about JAX is we have a very deep catalog of mice Cox says. We can breed the models with specific mutations to target but we also will have mutations develop by chance in some mice.These so-called spontaneous mutations are important because if they impact peripheral neuropathy motor neuron disease or muscular dystrophy they may relate in some way to ALS. By researching these genetic mutations Cox can figure out why they occurred and how the negative symptoms emerged.Every gene we isolate and identify has the potential to help a researcher says Cox so well keep working through the genes until we get a clearer picture of diseases like SMA and ALS.Empowering ALS therapeutic research building the factoryJAX isnt just working on isolating genes associated with ALS. As well as trying to create and improve genetic mouse models for ALS research Cat Lutz Ph.D. Director of the Mouse Repository and the Rare and Orphan Disease Center also works with major drug companies to evaluate potential therapeutics in-house. The advantage of running therapeutic testing through JAX Lutz says is that everything needed is all in one place.We built the factory Lutz says. We want to provide a universal and standardized test center for therapeutic companies where they can get excellent data quickly and efficiently.At JAX scientists can do genetic model-based research much more quickly than they could at their home institution. Lutz says that if a research group tried to run some of these studies independently obtaining the valuable data could easily take two years. At JAX that process typically takes just six months. This work has not just delivered vital information about potential therapeutics but significant gains in general knowledge about ALS itself.A few years ago we only had a few gene associations with ALS Lutz says Now thats shot up to well over 20.Empowering ALS researchersSince Lutz began working with so many organizations the ALS mouse models have become more advanced.We share all of the models that we create its standard practice Lutz says It may seem counterintuitive to growing intellectual property but thats not what were trying to achieve. This will give patients and researchers the best hope and chance Lutz says. This is our policy sharing everything we have.Word has gotten out to the ALS research world that JAX is a great place to evaluate new therapeutics. Lutz says big industry players regularly reach out to her and they dont even need to solicit big grants and contracts anymore.We have big companies and groups contacting us says Lutz We have the power to step in and complete whatever part of the research thats needed.New ALS treatments on the horizonWhen it comes to future therapeutics for ALS Lutz identified two prospects that she thinks look promising.The first is targeting a type of inflammation called oxidative stress and damage. Many drugs target this specific type of inflammation and they are getting better and better. They can delay ALS symptoms and give people more time but it is not a complete preventative or a cure.The second promising development is all about genetics. Some genetic pathways that cause ALS are known to researchers and drugs have emerged that can knock down or silence the mutated or damaged gene that brings about ALS.If we can find these pathways and use genetic models to gain insight says Lutz then we may be able to develop treatments that are more effective to more people.